Novian Health

  • About Us
    • Overview
    • Management
    • Board Of Directors
    • Investors
  • Research & Products
    • Novilase® Breast Therapy
    • Clinical Trials & Registries
    • Publications
    • Intellectual Property
  • News
    • News & Press Releases
    • Media Coverage
    • Upcoming Events
  • Contact
    • Careers

Novian Health Awarded New Patent for Breast Tumor Treatment Technology (28 Sept 2011)

September 28, 2011 by Novian Health

Sep. 28, 2011
Contact: Liz Dowling, (415) 3888-2794
Dowling & Dennis Public Relations
E-mail:Liz@DowlingDennis.net

CHICAGO –Novian Health, developer of Novilase® Breast Therapy, announced that the company has received a Notice of Allowance for a new patent. The U.S. patent,Application No. 11/957,040, covers probe holders for interstitial energy treatment. The technology enables precise positioning of the laser and temperature monitoring probes during image-guided interstitial laser therapy.
.
The newly allowed patent comes on the heels of Novian Health’s announcement this summer that the U.S. Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) for the company to conduct a multi-center study of its Novilase Interstitial Laser Therapy (ILT) System. The company is currently qualifying sites and investigators for that study.

Novian developed the ILT System for the ablation of small (up to 20 mm) malignant breast tumors. The company has previously received FDA 510(k) clearance for the treatment of breast fibroadenomas and currently offers Novilase at breast centers around the country that are participating in its ABLATE registry.

“The new patent covers technology that adds to the precision of Novilase therapy and eliminates technique variation, ” said Henry “Chip” Appelbaum, President and CEO of Novian Health. “This achievement further validates Novilase technology — and buttresses our already strong portfolio of intellectual property covering the monitoring and controlling of tumor ablation.”

About Novilase

Novilase is a laser-based device for destroying tumors. This minimally invasive alternative to conventional surgery provides a safe tumor treatment alternative while preserving the patient’s options for additional procedures or adjunctive therapies. This image-guided outpatient procedure does not require general anesthetic or a hospital stay. Multiple tumors can be treated during a single visit. Therapy outcomes may be assessed using a variety of currently available imaging technologies and other methods. Therapy consists of physician placement of two small gauge needles into the tumor site after localanesthetic, followed by initiation of the computer-controlled Novilase system. Treatment times vary from 15-30 minutes

About Novian Health

Novian Health Inc., located in Chicago, is a privately held medical device company with proprietary technology for the treatment of tumors using Interstitial Laser Therapy (ILT). Developed as an alternative to surgery, the company’s technology uses parametrically controlled heating for the ablation of tumors.Image-guided treatment of breast tumors is the first application of the technology, and Novilase also has the potential to treat tumors elsewhere in the body.
For more information, call (312) 266-7200 or access www.novianhealth.com and www.novilase.com

Download PDF

Related Posts

  • Novian Health Awarded New Patent for Breast Cancer Treatment Technology (05 Dec 2013)
  • Novian Health Receives FDA Approval to Study Breast Cancer Therapy (14 July 2011)
  • Novian Health Founder Is Honored as Breast Cancer Leader by Chicago Komen Affiliate (20 Oct 2011)
  • Novilase Treatment for Benign Breast Tumors Featured at Breast Surgeons Meeting (04 May 2009)
  • Breast Tumor Laser

Filed Under: Press Release 2011

Recent Posts

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

ARCHIVES

  • December 2022
  • September 2021
  • August 2021
  • July 2021
  • February 2021
  • September 2020
  • June 2020
  • September 2019
  • July 2019
  • June 2019
  • December 2015
  • December 2014
  • September 2014
  • May 2014
  • December 2013
  • April 2013
  • February 2013
  • April 2012
  • October 2011
  • September 2011
  • July 2011
  • November 2010
  • December 2009
  • November 2009
  • October 2009
  • May 2009
  • June 2008
  • March 2008
  • October 2007
  • June 2007

Categories

  • Archives
  • Press Release 2011
  • Press Release 2012
  • Press Release 2013
  • Press Release 2014
  • Press Release 2015
  • Press Release 2019
  • Press Release 2020
  • Press Release 2021
  • Press Release 2022

CONTACT US

Novian Health Inc.
(Headquarters)
Novian Health Inc.
(Manufacturing)
222 W Merchandise Mart Plaza
Suite 1230
Chicago, Illinois 60654
1205 E State Avenue
Tonganoxie, KS 66086
Office: 312-266-7200 Office: 312-266-7200
Fax: 312-266-7202 Fax: 312-266-7202
Email: info@novianhealth.com Email: info@novianhealth.com

    

LATEST NEWS

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

Copyright © 2023 Novian Health. All Rights Reserved. Powered by